J Korean Ophthalmol Soc > Volume 55(8); 2014 > Article
Journal of the Korean Ophthalmological Society 2014;55(8):1155-1161.
DOI: https://doi.org/10.3341/jkos.2014.55.8.1155    Published online August 15, 2014.
Comparison of Intravitreal Bevacizumab Alone Injection and Intravitreal Combination Low-Dose Bevacizumab-Triamcinolone Injection or Diabetic Macular Edema.
Byoung Seon Kim, In Young Chung, Jong Moon Park, Yong Seop Han
1Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea. medcabin@hanmail.net
2Gyeongsang Institute of Health Science, Gyeongsang National University, Jinju, Korea.
당뇨황반부종에서 베바시주맙 단일주입과 저용량 베바시주맙-트리암시놀론 혼합주입 단기효과 비교
김병선1⋅정인영1,2⋅박종문1,2⋅한용섭1,2
Department of Ophthalmology, Gyeongsang National University School of Medicine1, Jinju, Korea
Gyeongsang Institute of Health Science, Gyeongsang National University2, Jinju, Korea
Abstract
PURPOSE
To report the effects and intraocular pressure results of intravitreal bevacizumab alone injection compared with intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection in patients with diabetic macular edema. METHODS: In total, 40 eyes of 40 patients diagnosed with diabetic macular edema were evaluated. Of these, 20 eyes of 20 patients were injected with intravitreal bevacizumab (1.25 mg/0.05 mL) and 20 eyes of 20 patients were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best corrected visual acuity (BCVA), central macular thickness, and intraocular pressure of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection. RESULTS: In both the intravitreal bevacizumab and the low-dose bevacizumab combined with low-dose triamcinolone groups, BCVA increased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). In addition, in both groups, neither intraocular pressure (IOP) nor central macular thickness increased significantly at 1 month, 2 months, or 3 months after injection (p > 0.05). The BCVA, IOP, and central macular thickness (CMT) at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05). CONCLUSIONS: The BCVA of both groups increased significantly, and the CMT of both groups decreased significantly in patients with diabetic macular edema. The injection of low-dose intravitreal bevacizumab combined with low-dose intravitreal triamcinolone may be useful for the treatment of diabetic macular edema.
Key Words: Diabetic macular edema;Intravitreal bevacizumab injection;Intravitreal triamcinolone injection


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next